| Trial ID: | L5301 |
| Source ID: | NCT02535299
|
| Associated Drug: |
Liraglutide
|
| Title: |
Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment
|
| Acronym: |
Par-4；GLP-1
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
GLP-1；Metformin；Telomere-telomerase System；Par-4
|
| Interventions: |
DRUG: Liraglutide|DRUG: Metformin
|
| Outcome Measures: |
Primary: physiological parameter:glycosylated hemoglobin A1c, up to 6 months;;HbA1c was measured by a certified hospital laboratory according to established and approved protocols, up to 6 months; | Secondary: physiological parameter:the concentration of Par-4, up to 6 months;;secretary Par-4 were detected with Par-4 ELISA kit (MBL, USA), up to 6 months;|physiological parameter:telomere length, up to 6 months;;Telomere length was measured via fluorescence in situ hybridization using flow cytometry, up to 6 months;|physiological parameter:telomease activity, up to 6 months;;Telomerase activity was measured using the TeloTAGGG Telomerase PCR ELISAPLUS kit (Roche Diagnostics, Mannheim, Germany), up to 6 months;|physiological parameter:TNF-α, up to 6 months, TNF-a levels were measured by commercial ELISA kit following the manufacturer's instructions;TNF-a levels were measured by commercial ELISA kit following the manufacturer's instructions;(MBL, USA), up to 6 months;
|
| Sponsor/Collaborators: |
Sponsor: Third Military Medical University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
200
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2016-06
|
| Completion Date: |
2019-12
|
| Results First Posted: |
|
| Last Update Posted: |
2016-09-13
|
| Locations: |
Southwest Hospital of the Third Military Medical University, Chongqing, Chongqing, 400038, China
|
| URL: |
https://clinicaltrials.gov/show/NCT02535299
|
